DGAP-News

amp biosimilars announces Klaus K. Wilgenbus as new CEO

DGAP-News: amp biosimilars AG / Key word(s): Change of Personnel
amp biosimilars announces Klaus K. Wilgenbus as new CEO

28.06.2016 / 08:30
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

amp biosimilars announces Klaus K. Wilgenbus as new CEO

- Experienced industry executive to start as new CEO on July 1
- Founding CEO Marc W. Hentz steps down in a planned succession move

Hamburg, Germany, June 28 2016 - amp biosimilars AG (ISIN: DE000A0SMU87), a
company specializing in the development of high-quality biosimilars, today
announced that Klaus K. Wilgenbus will lead the firm as the new CEO from
July 1, 2016.

In 2014 Klaus Wilgenbus retired as Corp. Senior VP Business Development
Licensing and Strategy from Boehringer Ingelheim (BI). During his 18 year
tenure at BI he held various positions covering Business Development, R&D,
innovation management, corporate and commercial strategy, and
organizational development. Under his leadership BI has entered into more
than 200 strategic transactions incl. R&D collaborations, global
co-promotion and co-marketing alliances, JV's and merger and acquisitions
with business partners from North-America, EU and Asia. Klaus Wilgenbus
also served on various boards such as Karolinska Development AB (Solna
Sweden), Actimis Inc. (San Diego) and Boehringer Ingelheim Deutschland GmbH
& Co KG and represented BI at the Board of (US) BIO. After 2014 Klaus
Wilgenbus served as interim-CEO at Karolinska Development AB and advised as
independent consultant small to mid sized biotech companies and life
sciences investors in the areas of corporate strategy, fundraising and
business transactions. Wilgenbus was trained as a physician in Germany and
the US and holds an MD from RWTH Aachen.

"It's an exciting time to be joining amp biosimilars, with the company's
product and deal pipeline growing rapidly" said Wilgenbus. "I look forward
to joining the amp team in order to advance the development of new
high-quality therapies for patients in both the pharmerging and the
regulated markets, the primary focus of the work at amp."

Founding CEO Dr. Marc W. Hentz retires from the post in a planned
succession move. "I am excited that we can implement our plan to attract an
experienced industry leader to join amp for its next phase of corporate
development. The Board's appointment of Klaus Wilgenbus is a testimony to
our success and strategic direction, and I sincerely congratulate him.